*By Carlo Versano* Tilray, the Canadian cannabis company swiftly becoming one of the most talked-about stocks of the year, was up as much as 50 percent on Wednesday morning, leading a continued bull run in pot stocks and putting its market cap above established companies like Macy's and Viacom. Tilray President and CEO Brendan Kennedy [said](https://www.cnbc.com/2018/09/18/tilray-ceo-investing-in-pot-great-hedge-for-alcohol-drug-companies.html) on Tuesday that pharmaceutical and alcohol companies need to consider partnering with cannabis suppliers as a hedge against their core businesses. Those comments, along with the halo effect of Tilray saying it earned approval to provide medical marijuana for a U.S. clinical study, helped send shares over $200 apiece ー they debuted on the Nasdaq at $17 just two months ago. Citron Research, whose bearish bets on stocks can be market-moving, [tweeted](https://twitter.com/CitronResearch/status/1042395769372909568) on Wednesday morning that Tilray's run is "beyond comprehension" and that it will continue to be short the stock "until rationality sets in." That followed another less-than-favoratble [piece](https://www.barrons.com/articles/marijuana-stocks-coca-cola-aurora-1537235413) from Barron's that said, "even the bulls see a bubble." But with the legal sales of cannabis in Canada now less than a month away ー and investors jockeying for position ー the sector could continue on its high, at least in the short-term. Shares of both Canopy Growth and Aurora Cannabis have also seen double-digit percent increases since they've received interest from Constellation and Coca-Cola, respectively.
